Drug Profile
BLI 1009
Alternative Names: BLI-1009Latest Information Update: 07 Sep 2020
Price :
$50
*
At a glance
- Originator BioLite Inc
- Class Anti-ischaemics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Stroke
Most Recent Events
- 17 Feb 2016 No development reported - Phase-III for Stroke in Taiwan (unspecified route)
- 30 Jan 2013 Phase-III clinical trials in Ischaemia in Taiwan (unspecified route)
- 30 Jan 2013 Phase-III clinical trials in Stroke in Taiwan (unspecified route)